Home › Companies › Standard BioTools Inc. › 2025-2026

Standard BioTools Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Standard BioTools Inc.’s Form 8-K, filed 2026-06-18 (Item 5.07 on EDGAR). Page generated 04 October 2026.

7Ballot items
149Asset managers
1,000Fund votes
2026-06-17Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Standard BioTools Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Standard BioTools Inc.

These tallies are Standard BioTools Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Standard BioTools Inc. — official shareholder meeting results, meeting held 2026-06-17
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Michael Egholm, Ph.D.	236,313,971	--	--	13,467,627	86,119,046	Majority: yes
Elect Director: Thomas Carey	227,843,498	--	--	21,938,100	86,119,046	Majority: yes
Elect Director: Eli Casdin	234,717,465	--	--	15,064,133	86,119,046	Majority: yes
Proposal 2: Advisory Vote on Approval of Executive Compensation.	209,778,412	36,318,595	3,684,591	--	86,119,046	Passed
Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm.	330,172,606	652,236	5,075,802	--	--	Passed
Proposal 4: Approval of the 2026 Equity Incentive Plan.	228,342,854	17,821,911	3,616,833	--	86,119,046	Passed
Proposal 5: Approval of the Amendment to the Amended and Restated 2017 Employee Stock Purchase Plan.	237,474,844	12,276,507	30,247	--	86,119,046	Passed

Source: Standard BioTools Inc., Form 8-K, filed with the SEC on 2026-06-18 — read the filing on EDGAR.

How asset managers voted at the Standard BioTools Inc. 2025-2026 meeting

Each item below shows how the 149 asset managers that disclosed a Standard BioTools Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 7 wordings of this item as funds reported it.

85% Passed · of votes cast

FOR 85%AGAINST 15%

FOR: 209,778,412AGAINST: 36,318,595

Standard BioTools Inc.’s own tally for this item (“Proposal 2: Advisory Vote on Approval of Executive Compensation.”): 209,778,412 for, 36,318,595 against — passed, per its Form 8-K filed 2026-06-18 (Item 5.07). Of all 390,071,506 outstanding shares: 53.8% for, 9% against (63% of the company cast a for/against vote).

The 148 asset managers below cast 85% of the shares they voted on this item FOR (198,646,202 for, 35,950,034 against).

FOR 83%AGAINST 15%

FOR: 198,646,202 (83.4%)AGAINST: 35,950,034 (15.1%)ABSTAIN: 3,582,715 (1.5%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy s” at Standard BioTools Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Casdin Capital, LLC	87,932,732	0	0	For
VIKING GLOBAL INVESTORS LP	58,651,170	0	0	For
BlackRock	19,700,509	2,450	0	For
Vanguard	17,442,743	109,443	14	For
GEODE CAPITAL MANAGEMENT, LLC	0	6,939,872	0	Against
Fidelity	130,755	6,139,349	0	Against
State Street	5,257,132	87,129	0	For
Neuberger Berman	0	5,175,040	0	Against
Charles Schwab	0	4,830,599	0	Against
Royce	0	0	3,582,634	Abstain
Morgan Stanley	2,971,115	141,511	0	For
Peapod Lane Capital LLC	0	1,954,172	0	Against
Northern Trust	0	1,429,772	0	Against
Sone Capital Management, LLC	1,340,507	0	0	For
MELLON INVESTMENTS Corp	0	1,090,466	0	Against
AQR	0	1,043,839	0	Against
STALEY CAPITAL ADVISERS INC	750,000	0	0	For
Maryland State Retirement & Pension System	0	708,239	0	Against
Nuveen	661,204	0	0	For
TIAA	628,316	0	0	For
DE Shaw	0	571,016	0	Against
Equitable	348,210	181,640	0	For
QUANTITATIVE MASTER SERIES LLC	509,005	0	0	For
Citadel	454,799	0	0	For
Amova Asset Management Co., Ltd.	0	424,840	0	Against

Showing the 25 largest of 148 asset managers. See all 148 in the interactive database.

2. To approve the Standard BioTools Inc. 2026 Equity Incentive Plan.

COMPENSATIONCompany result: Passed

Combines 2 wordings of this item as funds reported it.

93% Passed · of votes cast

FOR 93%7%

FOR: 228,342,854AGAINST: 17,821,911

Standard BioTools Inc.’s own tally for this item (“Proposal 4: Approval of the 2026 Equity Incentive Plan.”): 228,342,854 for, 17,821,911 against — passed, per its Form 8-K filed 2026-06-18 (Item 5.07). Of all 390,071,506 outstanding shares: 59% for, 5% against (63% of the company cast a for/against vote).

The 40 asset managers below cast 98% of the shares they voted on this item FOR (39,988,421 for, 772,248 against).

FOR 90%8%

FOR: 39,988,421 (90.2%)AGAINST: 772,248 (1.7%)ABSTAIN: 3,582,648 (8.1%)

Largest asset managers voting on “To approve the Standard BioTools Inc. 2026 Equity Incentive Plan.” at Standard BioTools Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	15,069,581	118,211	14	For
BlackRock	11,275,392	0	0	For
Fidelity	6,166,712	91,271	0	For
Royce	0	0	3,582,634	Abstain
Charles Schwab	2,415,261	0	0	For
Neuberger Berman	1,037,137	0	0	For
Morgan Stanley	785,871	10,506	0	For
TIAA	628,316	0	0	For
Equitable	529,850	0	0	For
QUANTITATIVE MASTER SERIES LLC	509,005	0	0	For
TRUST FOR PROFESSIONAL MANAGERS	356,515	0	0	For
Global X	252,206	0	0	For
Lincoln Financial	208,900	0	0	For
AIG/SunAmerica	0	148,306	0	Against
Bridge Builder Trust	127,572	0	0	For
Invesco	120,879	0	0	For
Northern Trust	120,675	0	0	For
Pacific Life	117,614	0	0	For
State Street	97,694	0	0	For
John Hancock	0	74,650	0	Against
Rangeley Capital, LLC	0	70,000	0	Against
Goldman Sachs	58,730	0	0	For
Voya	0	56,336	0	Against
SEI	49,600	0	0	For
ProShares	0	42,202	0	Against

Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.

3. Election of Directors: Eli Casdin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 234,717,465WITHHELD: 15,064,133

Standard BioTools Inc.’s own tally for this item (“Elect Director: Eli Casdin”): 234,717,465 for, 15,064,133 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 390,071,506 outstanding shares: 60% for, 4% withheld (64% of the company cast a for/withheld vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (43,403,755 for, 0 against).

FOR 98%

FOR: 43,403,755 (98.0%)ABSTAIN: 869,434 (2.0%)

Largest asset managers voting on “Election of Directors: Eli Casdin” at Standard BioTools Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	15,158,107	29,698	For
BlackRock	11,275,392	0	For
Fidelity	6,257,983	0	For
Royce	3,582,634	0	For
Charles Schwab	2,415,261	0	For
Neuberger Berman	1,037,137	0	For
Morgan Stanley	796,377	0	For
TIAA	0	628,316	Abstain
Equitable	348,210	181,640	For
QUANTITATIVE MASTER SERIES LLC	509,005	0	For
TRUST FOR PROFESSIONAL MANAGERS	356,515	0	For
Global X	252,206	0	For
Lincoln Financial	208,900	0	For
AIG/SunAmerica	148,306	0	For
Bridge Builder Trust	127,572	0	For
Invesco	120,879	0	For
Northern Trust	120,675	0	For
Pacific Life	117,614	0	For
State Street	97,694	0	For
John Hancock	74,650	0	For
Goldman Sachs	58,730	0	For
Voya	56,336	0	For
SEI	49,600	0	For
ProShares	42,202	0	For
Victory Capital	42,175	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

4. Election of Directors: Michael Egholm, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 236,313,971WITHHELD: 13,467,627

Standard BioTools Inc.’s own tally for this item (“Elect Director: Michael Egholm, Ph.D.”): 236,313,971 for, 13,467,627 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 390,071,506 outstanding shares: 61% for, 3% withheld (64% of the company cast a for/withheld vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (44,243,274 for, 0 against).

FOR 99.9%

FOR: 44,243,274 (99.9%)ABSTAIN: 29,915 (0.1%)

Largest asset managers voting on “Election of Directors: Michael Egholm, Ph.D.” at Standard BioTools Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	15,158,112	29,693	For
BlackRock	11,275,392	0	For
Fidelity	6,257,983	0	For
Royce	3,582,634	0	For
Charles Schwab	2,415,261	0	For
Neuberger Berman	1,037,137	0	For
Morgan Stanley	796,377	0	For
TIAA	628,316	0	For
Equitable	529,850	0	For
QUANTITATIVE MASTER SERIES LLC	509,005	0	For
TRUST FOR PROFESSIONAL MANAGERS	356,515	0	For
Global X	252,206	0	For
Lincoln Financial	208,900	0	For
AIG/SunAmerica	148,306	0	For
Bridge Builder Trust	127,572	0	For
Invesco	120,879	0	For
Northern Trust	120,675	0	For
Pacific Life	117,614	0	For
State Street	97,694	0	For
John Hancock	74,650	0	For
Goldman Sachs	58,730	0	For
Voya	56,336	0	For
SEI	49,600	0	For
ProShares	42,202	0	For
Victory Capital	42,175	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

5. Election of Directors: Thomas Carey

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 227,843,498WITHHELD: 21,938,100

Standard BioTools Inc.’s own tally for this item (“Elect Director: Thomas Carey”): 227,843,498 for, 21,938,100 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 390,071,506 outstanding shares: 58% for, 6% withheld (64% of the company cast a for/withheld vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (42,653,162 for, 0 against).

FOR 96%

FOR: 42,653,162 (96.3%)ABSTAIN: 1,620,027 (3.7%)

Largest asset managers voting on “Election of Directors: Thomas Carey” at Standard BioTools Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	15,173,158	14,647	For
BlackRock	11,275,392	0	For
Fidelity	6,257,983	0	For
Royce	3,582,634	0	For
Charles Schwab	2,415,261	0	For
Neuberger Berman	1,037,137	0	For
Morgan Stanley	796,377	0	For
TIAA	0	628,316	Abstain
Equitable	348,210	181,640	For
QUANTITATIVE MASTER SERIES LLC	509,005	0	For
TRUST FOR PROFESSIONAL MANAGERS	356,515	0	For
Global X	0	252,206	Abstain
Lincoln Financial	0	208,900	Abstain
AIG/SunAmerica	148,306	0	For
Bridge Builder Trust	127,572	0	For
Invesco	120,879	0	For
Northern Trust	0	120,675	Abstain
Pacific Life	117,614	0	For
State Street	0	97,694	Abstain
John Hancock	74,650	0	For
Goldman Sachs	58,730	0	For
Voya	56,336	0	For
SEI	0	49,600	Abstain
ProShares	42,202	0	For
Victory Capital	42,175	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

6. TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED 2017 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR ISSUANCE THEREUNDER BY 1,200,000 SHARES.

COMPENSATIONCompany result: Passed

95% Passed · of votes cast

FOR 95%

FOR: 237,474,844AGAINST: 12,276,507

Standard BioTools Inc.’s own tally for this item (“Proposal 5: Approval of the Amendment to the Amended and Restated 2017 Employee Stock Purchase Plan.”): 237,474,844 for, 12,276,507 against — passed, per its Form 8-K filed 2026-06-18 (Item 5.07). Of all 390,071,506 outstanding shares: 61% for, 3% against (64% of the company cast a for/against vote).

The 38 asset managers below cast 99.9% of the shares they voted on this item FOR (44,273,166 for, 22 against).

FOR 99.9%

FOR: 44,273,166 (100.0%)AGAINST: 22 (0.0%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED 2017 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER O” at Standard BioTools Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	15,187,782	22	For
BlackRock	11,275,392	0	For
Fidelity	6,257,983	0	For
Royce	3,582,634	0	For
Charles Schwab	2,415,261	0	For
Neuberger Berman	1,037,137	0	For
Morgan Stanley	796,377	0	For
TIAA	628,316	0	For
Equitable	529,850	0	For
QUANTITATIVE MASTER SERIES LLC	509,005	0	For
TRUST FOR PROFESSIONAL MANAGERS	356,515	0	For
Global X	252,206	0	For
Lincoln Financial	208,900	0	For
AIG/SunAmerica	148,306	0	For
Bridge Builder Trust	127,572	0	For
Invesco	120,879	0	For
Northern Trust	120,675	0	For
Pacific Life	117,614	0	For
State Street	97,694	0	For
John Hancock	74,650	0	For
Goldman Sachs	58,730	0	For
Voya	56,336	0	For
SEI	49,600	0	For
ProShares	42,202	0	For
Victory Capital	42,175	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

7. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2026.

AUDIT-RELATEDCompany result: Passed

Combines 2 wordings of this item as funds reported it.

99.8% Passed · of votes cast

FOR 99.8%

FOR: 330,172,606AGAINST: 652,236

Standard BioTools Inc.’s own tally for this item (“Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm.”): 330,172,606 for, 652,236 against — passed, per its Form 8-K filed 2026-06-18 (Item 5.07). Of all 390,071,506 outstanding shares: 85% for, 0.2% against (85% of the company cast a for/against vote).

The 38 asset managers below cast 99.9% of the shares they voted on this item FOR (44,243,291 for, 29,891 against).

FOR 99.9%

FOR: 44,243,291 (99.9%)AGAINST: 29,891 (0.1%)ABSTAIN: 8 (0.0%)

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm f” at Standard BioTools Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	15,158,129	29,669	8	For
BlackRock	11,275,392	0	0	For
Fidelity	6,257,983	0	0	For
Royce	3,582,634	0	0	For
Charles Schwab	2,415,261	0	0	For
Neuberger Berman	1,037,137	0	0	For
Morgan Stanley	796,377	0	0	For
TIAA	628,316	0	0	For
Equitable	529,850	0	0	For
QUANTITATIVE MASTER SERIES LLC	509,005	0	0	For
TRUST FOR PROFESSIONAL MANAGERS	356,515	0	0	For
Global X	252,206	0	0	For
Lincoln Financial	208,900	0	0	For
AIG/SunAmerica	148,306	0	0	For
Bridge Builder Trust	127,572	0	0	For
Invesco	120,879	0	0	For
Northern Trust	120,675	0	0	For
Pacific Life	117,614	0	0	For
State Street	97,694	0	0	For
John Hancock	74,650	0	0	For
Goldman Sachs	58,730	0	0	For
Voya	56,336	0	0	For
SEI	49,600	0	0	For
ProShares	42,202	0	0	For
Victory Capital	42,175	0	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

Largest Standard BioTools Inc. shareholders voting in 2025-2026

Ranked by the number of Standard BioTools Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 390,071,506 shares outstanding at the time of that meeting.

Top Standard BioTools Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Casdin Capital, LLC	22.54%
2	VIKING GLOBAL INVESTORS LP	15.04%
3	BlackRock	5.05%
4	Vanguard	4.50%
5	GEODE CAPITAL MANAGEMENT, LLC	1.78%
6	Fidelity	1.61%
7	State Street	1.37%
8	Neuberger Berman	1.33%
9	Charles Schwab	1.24%
10	Royce	0.92%

Reported Standard BioTools Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Standard BioTools Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Eli Casdin	24.06%	13D
VIKING GLOBAL INVESTORS LP	15.04%	13D
MAK CAPITAL ONE LLC	7.39%	13G
MAK Capital Fund LP	6.71%	13G
BlackRock	6.35%	13F
Vanguard Group	4.43%	13F
Morgan Stanley	1.97%	13F
State Street	1.68%	13F
Northern Trust	0.63%	13F
Charles Schwab	0.62%	13F

Percentages above are of 390,071,506 shares outstanding, as reported by Standard BioTools Inc. on its Form 10-K dated 2026-03-12 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Standard BioTools Inc.’s 10-K dated 2026-03-12. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Standard BioTools Inc.'s shareholder meeting held 2026-06-17, in the 2025-2026 proxy season, 149 asset managers reported how they voted on 7 ballot items in their SEC Form N-PX filings, covering 1,000 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers as disclosed… — the proposal passed with 85% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Standard BioTools Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-18.

Standard BioTools Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).